REFLECTION: A Clinical Practice Learning Program for Galleri®
NCT ID: NCT05205967
Last Updated: 2025-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
14633 participants
OBSERVATIONAL
2021-08-23
2026-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Galleri® in the Medicare Population.
NCT05673018
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study
NCT06523868
The Galleri® Community Research Program
NCT06603259
PATHFINDER 2: a Multi-Cancer Early Detection Study
NCT05155605
Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
NCT04241796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients who received the Galleri® test.
MCED
Multi-cancer early detection (MCED) test
SOC
Standard of care cancer screening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MCED
Multi-cancer early detection (MCED) test
SOC
Standard of care cancer screening
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has the ability to understand and the willingness to sign a written informed consent form (ICF);
* Participant is at least 22 years old at the time of consent;
* A provider or their designee has ordered the Galleri® test; and
* Participant has the ability to comprehend the participant questionnaires.
Exclusion Criteria
22 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GRAIL, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vincere Cancer Center
Scottsdale, Arizona, United States
Providence
Burbank, California, United States
Providence, St. Jude
Fullerton, California, United States
Providence, Mission
Mission Viejo, California, United States
Providence, Orange County
Orange, California, United States
VA Miami Health Care System
Miami, Florida, United States
James A. Haley Veterans Hospital (VA Tampa)
Tampa, Florida, United States
Southeast Louisiana Veterans Health Care System (SLVHCS) (VA New Orleans)
New Orleans, Louisiana, United States
Boston VA Research Institute (VA Boston)
Boston, Massachusetts, United States
Providence
Portland, Oregon, United States
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, United States
VA Wilkes Barre Medical Center
Wilkes-Barre, Pennsylvania, United States
Carolina Blood and Cancer Care Associate
Lancaster, South Carolina, United States
Carolina Blood and Cancer Care Associates
Rock Hill, South Carolina, United States
VA Salt Lake City Health Care System (VASLCHCS)
Salt Lake City, Utah, United States
WVU University Town Centre Family Medicine
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kortlever TL, Ferlizza E, Lauriola M, Borrelli F, Porro A, Spaander MCW, Bossuyt PM, Ricciardiello L, Dekker E. Diagnostic Accuracy of an Add-On, Blood-Based Screening Test for Colorectal Cancer in Two Established Screening Programmes. Aliment Pharmacol Ther. 2025 Jun;61(12):1935-1943. doi: 10.1111/apt.70141. Epub 2025 Apr 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GRAIL-MA-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.